Economics of New Oncology Drug Development
Top Cited Papers
- 10 January 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (2), 209-216
- https://doi.org/10.1200/jco.2006.09.0803
Abstract
Medical technology is increasingly costly in most fields of clinical medicine. Oncology has not been spared from issues related to cost, in part resulting from the tremendous scientific progress that has lead to new tools for diagnosis, treatment, and follow-up of our patients. The increasing cost of health care in general (and cancer care in particular) raises complex questions related to its effects on our economy and the citizens of our society. This article reviews the macroeconomic principles and individual behaviors that govern medical spending, and examines how cost disproportionately affects various populations. Our overall goal is to frame debate about health policy concerns that influence the clinical practice of oncology.Keywords
This publication has 15 references indexed in Scilit:
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- The Impact of Incremental Innovation in BiopharmaceuticalsPharmacoEconomics, 2006
- Pharmaceutical Development PhasesJournal of Pharmaceutical Finance, Economics & Policy, 2006
- The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003Health Affairs, 2006
- R&D Costs and Returns by Therapeutic CategoryDrug Information Journal, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Risks in new drug development: Approval success rates for investigational drugsClinical Pharmacology & Therapeutics, 2001
- Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994Clinical Pharmacology & Therapeutics, 1996
- Success rates for new drugs entering clinical testing in the United StatesClinical Pharmacology & Therapeutics, 1995
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991